Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study

Ann Oncol. 2021 Apr;32(4):427-430. doi: 10.1016/j.annonc.2021.02.002. Epub 2021 Feb 9.

Authors

E Agostinetto¹, M Ignatiadis²

Affiliations

¹ Medical Oncology Department, Institut Jules Bordet and Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Humanitas Clinical and Research Center-IRCCS, Humanitas Cancer Center, Rozzano, Milan, Italy.
² Medical Oncology Department, Institut Jules Bordet and Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: michail.ignatiadis@bordet.be.

PMID: 33571637
DOI: 10.1016/j.annonc.2021.02.002

No abstract available

Publication types

Editorial
Comment

MeSH terms

Aromatase Inhibitors* / therapeutic use
Breast Neoplasms* / drug therapy
Capecitabine
EGF Family of Proteins
Humans
Piperazines
Pyridines

Substances

Aromatase Inhibitors
EGF Family of Proteins
Piperazines
Pyridines
Capecitabine
palbociclib